Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis
- 1 March 1994
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 44 (3_part_1), 406
- https://doi.org/10.1212/wnl.44.3_part_1.406